IGM Biosciences Financial Statements (IGMS)
|
|
|
|
Report date
|
|
|
30.03.2021 |
29.03.2022 |
30.03.2023 |
07.03.2024 |
06.03.2025 |
|
31.07.2025 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
1.07 |
2.13 |
2.68 |
|
145.1 |
|
Operating Income, bln rub |
|
|
-83.3 |
-165.3 |
-228.0 |
-263.5 |
-208.6 |
|
-27.9 |
|
EBITDA, bln rub |
? |
|
-77.8 |
-157.4 |
-221.9 |
-255.2 |
-199.5 |
|
-31.3 |
|
Net profit, bln rub |
? |
|
-80.3 |
-160.7 |
-214.2 |
-246.4 |
-195.8 |
|
-53.4 |
|
|
OCF, bln rub |
? |
|
-67.3 |
-124.3 |
-5.85 |
-192.2 |
-153.0 |
|
-156.5 |
|
CAPEX, bln rub |
? |
|
17.5 |
13.2 |
10.2 |
12.4 |
5.85 |
|
2.19 |
|
FCF, bln rub |
? |
|
-84.8 |
-137.6 |
-16.1 |
-204.6 |
-158.8 |
|
-158.7 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
83.3 |
165.3 |
229.0 |
265.6 |
211.3 |
|
172.5 |
|
Cost of production, bln rub |
|
|
3.58 |
7.72 |
10.6 |
8.28 |
9.11 |
|
2.79 |
|
R&D, bln rub |
|
|
65.0 |
127.0 |
179.3 |
215.5 |
160.9 |
|
101.8 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
408.6 |
298.1 |
513.5 |
423.4 |
265.7 |
|
107.0 |
|
Net Assets, bln rub |
? |
|
-188.6 |
-353.7 |
-574.8 |
203.2 |
48.2 |
|
100.9 |
|
Debt, bln rub |
|
|
12.2 |
28.8 |
41.2 |
40.5 |
45.2 |
|
0.000 |
|
Cash, bln rub |
|
|
366.3 |
229.5 |
427.2 |
337.7 |
183.8 |
|
104.3 |
|
Net debt, bln rub |
|
|
-354.0 |
-200.8 |
-386.0 |
-297.2 |
-138.6 |
|
-104.3 |
|
|
Ordinary share price, rub |
|
|
88.3 |
29.3 |
17.0 |
8.31 |
6.11 |
|
4.74 |
|
Number of ordinary shares, mln |
|
|
30.7 |
33.5 |
41.5 |
52.3 |
60.5 |
|
61.5 |
|
|
Market cap, bln rub |
|
|
2 715 |
982 |
707 |
435 |
370 |
|
291 |
|
EV, bln rub |
? |
|
2 361 |
781 |
321 |
138 |
231 |
|
187 |
|
Book value, bln rub |
|
|
-189 |
-354 |
-575 |
203 |
48 |
|
101 |
|
|
EPS, rub |
? |
|
-2.61 |
-4.80 |
-5.16 |
-4.71 |
-3.24 |
|
-0.87 |
|
FCF/share, rub |
|
|
-2.76 |
-4.11 |
-0.39 |
-3.91 |
-2.62 |
|
-2.58 |
|
BV/share, rub |
|
|
-6.13 |
-10.6 |
-13.8 |
3.89 |
0.80 |
|
1.64 |
|
|
EBITDA margin, % |
? |
|
|
|
-20 756% |
-11 980% |
-7 446% |
|
-21.6% |
|
Net margin, % |
? |
|
|
|
-20 042% |
-11 569% |
-7 309% |
|
-36.8% |
|
FCF yield, % |
? |
|
-3.12% |
-14.0% |
-2.27% |
-47.1% |
-43.0% |
|
-54.5% |
|
ROE, % |
? |
|
42.6% |
45.4% |
37.3% |
-121.2% |
-406.4% |
|
-52.9% |
|
ROA, % |
? |
|
-19.7% |
-53.9% |
-41.7% |
-58.2% |
-73.7% |
|
-49.9% |
|
|
P/E |
? |
|
-33.8 |
-6.11 |
-3.30 |
-1.76 |
-1.89 |
|
-5.46 |
|
P/FCF |
|
|
-32.0 |
-7.14 |
-44.0 |
-2.12 |
-2.33 |
|
-1.84 |
|
P/S |
? |
|
|
|
661.1 |
204.1 |
138.0 |
|
2.01 |
|
P/BV |
? |
|
-14.4 |
-2.78 |
-1.23 |
2.14 |
7.68 |
|
2.89 |
|
EV/EBITDA |
? |
|
-30.4 |
-4.96 |
-1.45 |
-0.54 |
-1.16 |
|
-5.98 |
|
Debt/EBITDA |
|
|
4.55 |
1.28 |
1.74 |
1.16 |
0.69 |
|
3.33 |
|
|
R&D/CAPEX, % |
|
|
371.6% |
959.1% |
1 757% |
1 741% |
2 749% |
|
4 658% |
|
|
CAPEX/Revenue, % |
|
|
|
|
954.7% |
581.3% |
218.4% |
|
1.51% |
|
| IGM Biosciences shareholders |
